1 |
Na, J. H. and Choi, J. S. : Effect of naringin on the pharmacokinetics of nifedipine in rats. J. Kor. Pharm. Sci. 35, 101 (2005).
과학기술학회마을
|
2 |
Sorkin, E. M., Clissold, S. P. and Brogden, R. N. : Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs. 30, 182 (1985).
DOI
ScienceOn
|
3 |
Jang, M., Cai, L., Udeani, G. O., et al. : Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218 (1997).
DOI
|
4 |
Guengerich, F. P. : Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res. 48, 2946 (1988).
|
5 |
Chan, W. K. and Delucchi, A. B. : Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci. 67, 3103 (2000).
DOI
ScienceOn
|
6 |
Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res. 16, 225 (1999).
DOI
ScienceOn
|
7 |
Piver, B., Berthou, F., Dreano, Y., et al. : Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol. Lett. 125, 83 (2001).
DOI
ScienceOn
|
8 |
Chang, T. K. H., Chen, J. and Yu, C. T. : In vitro inhibition of rat CYP1A1 and CYP1A2 by piceatannol, a hydroxylated metabolite of resveratrol. Drug Metab. Lett. 1, 13 (2007).
DOI
ScienceOn
|
9 |
Soleas, G. J., Diamandis, E. P. and Golberg, D. M. : Resveratrol: a molecule whose time has come? and gone? Clin. Biochem. 30, 91 (1997a).
DOI
ScienceOn
|
10 |
Frankel, E. N., Waterhouse, A. L. and Kinsella, J. E. : Inhibition of human LDL oxidation by resveratrol. Lancet. 341, 1103 (1993).
|
11 |
Soleas, G. J., Diamandis, E. P. and Golberg, D. M. : Wine as a biological fluid: history, production, and role in disease prevention. J. Clin. Lab. Anal. 11, 287 (1997b).
DOI
ScienceOn
|
12 |
Constant, J. : Alcohol, ischemic heart disease, and the French paradox. Coronary Artery. Dis. 8, 645 (1997).
DOI
ScienceOn
|
13 |
Fruehauf, J. P. and Manetta, A. : Use of extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: Taxol resistance and MDR1 expression. Contrib. Gynecol. Obstet. 19, 39 (1994).
|
14 |
Grundy, J. S., Kherani, R. and Foster, R. T. : Sensitive highperformance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection. J. Chromatogr B. Biomed. Appl. 654, 146 (1994).
DOI
ScienceOn
|
15 |
Crespi, C. L., Miller, V. P. and Penman, B. W. : Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248, 188 (1997).
DOI
ScienceOn
|
16 |
Rocci, M. L. and Jusko, W. J. : LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine. 16, 203 (1983).
DOI
ScienceOn
|
17 |
Fauconneau, B., Waffo-Teguo, P., Huguet, F., et al. : Comparative study of radical scavenger and antioxidant properties of phenolic compounds from vitis vinifera cell cultures using in vitro tests. Life Sci. 61, 2103 (1997).
|
18 |
Han, H. K., Lee, I. K. and Choi, J. S. : Pharmacokinetic interaction between nifedipine and quercetin in rabbits. J. Kor. Pharm. Sci. 34, 283 (2004).
과학기술학회마을
|
19 |
Hong, S. P., Choi, D. H. and Choi, J. S. : Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. Cardiovascular. 26, 269 (2008).
DOI
|
20 |
Choi, J. S., Choi, B. C. and Kang, K. W. : Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrol. Pharmazie. 64, 49 (2009).
|
21 |
Guengerich, F. P., Brian, W. R. and Iwasaki, M. : Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 3A4. J. Med. Chem. 4, 1838 (1991).
|
22 |
Lee, J. K. and Choi, J. S. : Effect of morim on the pharmacokinetics of nifedipine in rats. Yakhak Hoeji 51, 169 (2007).
과학기술학회마을
|
23 |
Chaudhary, P. M. and Robinson, I. B. : Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 66, 85 (1991).
DOI
ScienceOn
|
24 |
Van Asperen, J., Van Tellingen, O., Sparreboom, A., et al. : Enhanced oral bilavailability of diltiazem in mice treated with the p-glycoprotein blocker. Br. J. Cancer. 76, 1181 (1997).
DOI
ScienceOn
|
25 |
Biedler, J. L. and Riehm, H. : Cellular resistance to actinomycin D in Chinese hamster cells in vitro: crossresistance, radioautographic, and cytogenetic studies. Cancer Res. 30, 1174 (1970).
|
26 |
Ford, J. M. : Modulators of multidrug resistance preclinical studies. Hematol. Oncol. Clin. N. Am. 9, 337 (1995).
|
27 |
Iribarne, C., Dréano, L. G., Bardou, J. F., et al. : Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicology 117, 13 (1997).
DOI
ScienceOn
|
28 |
Watkins, P. B., Wrighton, S. A., Schuetz, E. G., et al. : Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest. 80, 1029 (1987).
DOI
|
29 |
Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993).
DOI
ScienceOn
|
30 |
Kolars, J. C., Schmiedlin-Ren, P., Dobbins, 3rd W. O., et al. : Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102, 1186 (1992).
DOI
|
31 |
Gan, S. L., Moseley, M. A., Khosla, B., et al. : CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 24, 344 (1996).
|
32 |
Watkins, P. B. : The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27, 161 (1996).
|
33 |
Wacher, V. H., Silverman, J. A., Zhang, Y., et al. : Role of Pglycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87, 1322 (1998).
DOI
|
34 |
Henry, P. D. : Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. Am. J. Cardiol. 46, 1047 (1980).
DOI
ScienceOn
|
35 |
Nabekura, T., Kamiyama, S. and Kitagawa, S. : Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem. Biophys. Res. Commun. 327, 866 (2005).
DOI
ScienceOn
|
36 |
Walter, D. G., Gruchy, B. S., Renwick, A. G., et al. : The firstpass metabolism of nifedipine in man. Br. J. Clin. Pharmacol. 18, 951 (1984).
DOI
ScienceOn
|
37 |
Raemsch, K. and Sommer, J. C. : Pharmacokinetics and metabolism of nifedipine. Hypertension. 5, 18 (1983).
|
38 |
Bertelli, A. A. E., Giovanni, L., Stradi, R., et al. : Kinetics of trans- and cis-resveratrol (3,4',5-trihydroxystilbene) after red wine oral administration in rats. Int. J. Clin Pharmacol Res. 26, 77 (1996).
|